Table 2 Effectiveness in clinically evaluable patients and secondary outcomes at 90-days

Primary Outcome

Composite failure at 90-days^a, n (%)

9 (14)

Secondary Outcomes

Clinical failure^a, n (%)

9 (14)

 All-cause mortality

8 (13)

 Initiation of Gram-positive antibiotic for presumed failure

1 (2)

 Index Infection-related readmission

1 (2)

Microbiological failure^{a ,} n (%)

3 (5)

Infection-related readmission^b, n (%)

8 (11)

Acute Kidney Injury^b, n (%)

19 (26)

 Prior to Oritavancin administration

19 (26)

 AKI after Oritavancin administration

3 (4)

Infusion-related reactions^b, n (%)

2 (3)

Loss to follow-up^b, n (%)

8 (11)